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PRELIMINARY AND SHORT REPORT
SPECTROPHOTOMETRIC AND ELECTROPHORETIC PATTERNS OF SERA OF
PATIENTS WITH POLYMORPHOTJS LIGHT ERTIPTION*
MILTON M. CARN, M.D., EDWIN J. LEVY, M.D., J. M. VANDENBELT, PH.D. AND
BERTRAM SHAFFER, M.D.
The antimalarial drugs are useful agents for
the treatment and prevention of polymorphous
light eruptions (1—3). Their mode of action in this
disease is not known. In one study it was shown
that they suppress the abnormal inflammatory
papular response but do not alter the normal
reaction to ultraviolet light in patients with
polymorphous light eruptions (4). In a recent
study these drugs were found concentrated in the
epidermis, relative to the dermis, but in such
amounts that spectrophotometrically, at least,
they did not appear to act as light screening
agents (5).
This study was undertaken to determine any
alterations in the light absorption spectra, or in
the electrophoretic patterns of the sera of pa-
tients with the papular prurigo-type of poly-
morphous light eruption, prior to the onset of
their eruption, after the eruption appeared, and
after administration of the drug amodiaquin.t
METHOD
Five (5) patients with a history of the papular
type of polymorphous light eruption each summer
for the previous 6 to 23 years were included in this
study. Specimens of blood serum were obtained
(a) in February 1957 when each of the patients was
free of the eruption; (b) in the spring of 1957 after
sunlight exposure had induced the eruption; and
(c) after administration of amodiaquin with suc-
cessful suppression of the polymorphous light
eruption in all patients (3).
Ultraviolet and visible absorption spectra were
determined on a Cary Recording Spectropho-
tometer after dilution of the sera into 0.1 N 1101
and 0.1 N NaOH. These media were selected be-
cause each yields a characteristic curve pattern
(mostly tyrosine and tryptophane absorption)
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with a characteristic change in pattern from acidic
to basic solution.
Electrophoresis was performed on the serum
specimens with the Aminco-Stern apparatus.
Samples of sera were diluted two times and di-
alyzed against veronal buffer, pH 8.6, ionic
strength 0.1.
Serum from a normal individual free of this
disease, was used as the control.
RESULTS
There was no significant modification in the
character of the serum spectra as a result of treat-
ment, in any part of the ultraviolet region, in-
cluding that between 250—260 mu.
In the region near 340 mu. where amodiaquin
has a pronounced band, there was no evidence of
this absorption in the sera of patients receiving
the drug.
In the visible region there were considerable
differences between the serum spectra of different
patients and also between specimens from the
same patients at different times not suggestive of
any sequence or pattern.
Electrophoretic patterns were undifferentiable
from normal when the individuals were free of
eruption, at the height of eruption, and after sup-
pression with amodiaquin.
CONCLUSIONS
There were no characteristic changes in the
ultraviolet and visible light absorption spectra,
or in the electrophoretic patterns, of patients with
the papular form of polymorphous light eruption,
whether these studies were done when the eruption
was in a quiescent phase, at the height of eruption,
or after Suppression with amodiaquin.
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